De­mand-con­strained Covid vac­cine mar­ket may push South Africa's As­pen to change its di­rec­tion

Last year, South African man­u­fac­tur­er As­pen Phar­ma­care was in a good po­si­tion, as the com­pa­ny opened new man­u­fac­tur­ing lines and start­ed to pump out J&J’s sin­gle-dose Covid-19 vac­cine — even hitch­ing its wag­on to mak­ing its own ver­sion of the vac­cine to sell to African mar­kets.

But this year the com­pa­ny is fac­ing the heat as it has not re­ceived a sin­gle or­der for the Covid vac­cine, a New York Times re­port showed. And now, a re­port from Reuters points to more bad news for the com­pa­ny.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER